Navigation Links
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
Date:2/6/2013

of its revenue from Neupogen franchise. However, the drug would go off patent protection by the end of 2013 and the loss of exclusivity is expected to affect Amgen. Neupogen faces stiff competition from the companies like Novartis in the markets outside of the U.S. and these competing companies may launch their products in the U.S., causing further damage. However, the company has somewhat strong drug candidates including AMG145, a cholesterol drug candidate.

Amgen stock grew over 25 percent in the past 12 months. It also offers good dividend yield of 2.17 percent. The company is likely to increase its dividend in the future, thus offering good returns to the investors. Amgen is also growing through acquisitions as it recently completed the purchase of Icelandic company decode Genetics.

Peregrine Struggles with Cancer Drug Development

Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral infections. It also develops treatments for cancers. It is currently engaged in developing treatment for non-small cell lung cancer. If successful, the company will make big fortunes as non-small cell lung cancer accounts for about 80 percent of lung cancer cases. However, the company does not have very solid track record. The drug candidate bavituximab has been controversial as it led to the stock's massive tumble in September 2012. Sign up to download the free technical analysis on Peregrine Pharmaceuticals at

http://www.StockCall.com/PPHM020613.pdf  

Peregrine is a small company with the market capitalization of less than $300 million. The stock is quite volatile as well. The company is currently looking to get past the phase II for bavituximab. Overall, the stock may be held if it is already in your portfolio. On the upside, the stock is currently trading about 50 percent below its 52-week high, thus in case of positive news on its
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 , La ... contribuye a adquirir tolerancia a la proteína de ... proteína de la leche de la vaca (APLV) es la ... Hasta ahora, la APLV se trataba eliminando las ... demostrado que es posible adquirir tolerancia oral en ...
(Date:10/30/2014)... , Oct. 29, 2014 The global ... of test type, technology, product, and geography. The ... highest growth rate in the newborn screening market ... growth is attributed to various nations opting for ... fundamental instrument used for expanded newborn screening. Furthermore, ...
(Date:10/30/2014)... The global market for human vaccines ... of new vaccines. These new products and other ... The Kalorama information report examines the global market ... vaccines for diseases that are already vaccine-preventable. ... communities from diseases spread by person-to-person transmission. The ...
Breaking Medicine Technology:Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
... , SAN DIEGO, Nov. 6 Ardea Biosciences, Inc. ... the development of small-molecule therapeutics for the treatment of ... recent accomplishments and financial results for the third quarter ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO ) , "Since our last ...
... Inc., in collaboration with scientists at the Centers for Disease ... of Hong Kong, announced today the publication of two articles ... studies suggest that DAS181 (Fludase ® ) may play a ... Pandemic Influenza A(H1N1) and drug-resistant influenza. , DAS181 is ...
Cached Medicine Technology:Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4
(Date:10/30/2014)... cancer care respects the fact that a patient,s ... requires treatment. Over a third of cancer patients ... of their conditions. And, increasingly, care providers are ... patients navigate mental health challenges. A University of ... journal Psycho-Oncology asks an important question: ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
(Date:10/29/2014)... certain prostate cancer medications are linked with an increased ... congestive heart failure or prior heart attacks. Published in ... and patients weigh the benefits and risks of the ... levels of male hormones in the body to prevent ... treatment for prostate cancer. Despite its anticancer effects, ADT ...
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/28/2014)... NY (October 27, 2014)—Although oral hormonal therapy is ... women with hormone receptor–positive tumors, about one-half of ... A study by Columbia University Medical Center (CUMC) ... aromatase inhibitors (the most common type of hormone ... brand-name counterparts, increased treatment adherence by 50 percent. ...
Breaking Medicine News(10 mins):Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Gentle caffeine boost for premature babies 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:New insights into the development of ciliopathies 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3
... , MONDAY, Jan. 17 (HealthDay News) -- Patients at high ... detect the deadly skin cancer at an early stage, new ... some people from having a doctor examine their skin for ... Archives of Dermatology . People at high risk for ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... flares of multiple sclerosis (MS), but does not help ... guidelines say. Plasma exchange, or plasmapheresis, is also ... chronic inflammatory demyelinating polyneuropathy and it may be considered ...
... poor can prevent young children from reaching their full genetic potential ... University of Texas at Austin looked at 750 sets of twins ... and 2 years. During the tests the children were asked to ... placing three cubes in a cup, and matching pictures. At ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... called calcium channel blockers face an increased risk of ... shock if they take certain antibiotics, Canadian researchers warn. ... to patients taking calcium channel blockers, can increase the ...
... -- Among middle-school students, friendships can make the difference ... Students whose friends are socially active in positive ways ... badly get lower grades, according to the results of ... also staying away from deviant peers was associated with ...
... surgery remains significantly different when compared to the patient,s opposite ... a study that updated prior findings, researchers used X-rays providing ... relation to the shoulder blade, to compared motion in the ... tendon tears and no symptoms in their other shoulders. An ...
Cached Medicine News:Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 3Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 2Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 3Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 3Health News:Friends a Big Influence on Grades in Middle School: Study 2Health News:Henry Ford Hospital study: Shoulder function not fully restored after surgery 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers. Polyethylene cover....
Medicine Products: